Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,623 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 420 | Daiichi SankyoINDUSTRY | 4 | Aug 24, 2026 | clinicaltrials |
| NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 400 | MedImmune LLCINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | active not recruiting | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05765851 | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 108 | Daiichi SankyoINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT07306559 | A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 187 | Boehringer IngelheimINDUSTRY | 6 | Aug 21, 2026 | clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT06154291 | FIH XON7 in Advanced/Metastatic Solid Tumors(FIPO23) | recruiting | Phase 1 / Phase 2 | 255 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT00412503 | Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents | completed | Phase 1 | — | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02215720 | Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors(TORERO) | completed | Phase 1 | 45 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02220049 | Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors(VELDAY) | completed | Phase 1 | 18 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT05356741 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | recruiting | Phase 1 / Phase 2 | 645 | Vir Biotechnology, Inc.INDUSTRY | 5 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT01167530 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer(RAD001) | completed | Phase 1 | 26 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03436485 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer(CYPIDES) | active not recruiting | Phase 1 / Phase 2 | 204 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Aug 14, 2026 | clinicaltrials |
| NCT04774718 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 11 | Aug 14, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT02217956 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma(CHIPASTIN) | completed | Phase 1 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02515877 | Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers(HPV-RX) | completed | Phase 1 | 15 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | completed | Phase 1 | 134 | AbbVieINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT04707300 | Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)(HTLP-ONCO) | recruiting | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05491317 | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 13 | GenmabINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy(Epi-RCHOP) | active not recruiting | Phase 1 / Phase 2 | 214 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | active not recruiting | Phase 1 / Phase 2 | 61 | MedImmune LLCINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT06162572 | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 102 | Servier Bio-Innovation LLCINDUSTRY | 14 | Aug 11, 2026 | clinicaltrials |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT06067841 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 140 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 10, 2026 | clinicaltrials |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | recruiting | Phase 1 | 190 | Immunome, Inc.INDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT07754006 | Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication(CAMPSIS) | not yet recruiting | Phase 1 | 6 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT06542250 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.(TITANium) | recruiting | Phase 1 / Phase 2 | 174 | AstraZenecaINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials